Quick Answer
NOVAVAX INC reported Total Revenue of $1.12 billion for fiscal year 2025.
NOVAVAX INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.12B +64.7% |
$682.16M -30.7% |
$983.71M -50.4% |
$1.98B +72.9% |
$1.15B +141.0% |
$475.60M +2448.5% |
| Net Income | $440.30M +334.8% |
-$187.50M +65.6% |
-$545.06M +17.2% |
-$657.94M +62.3% |
-$1.74B -316.9% |
-$418.26M -215.2% |
| Diluted EPS | $2.58 +309.8% |
-$1.23 +77.3% |
-$5.41 +35.7% |
-$8.42 +64.1% |
-$23.44 -222.4% |
-$7.27 -31.9% |
| Total Assets | $1.18B -24.6% |
$1.56B -13.2% |
$1.80B -20.4% |
$2.26B -12.3% |
$2.58B +62.8% |
$1.58B +815.0% |
| Cash and Equivalents | $240.63M -54.6% |
$530.23M -6.7% |
$568.50M -57.5% |
$1.34B -11.8% |
$1.52B +173.8% |
$553.40M +602.1% |
| Stockholders Equity | -$127.75M +79.5% |
-$623.84M +13.0% |
-$716.93M -13.1% |
-$634.08M -80.3% |
-$351.67M -156.1% |
$627.21M +437.2% |
| R&D Expense | $342.32M -12.5% |
$391.17M -47.0% |
$737.50M -40.3% |
$1.24B -51.3% |
$2.53B +239.3% |
$747.03M +556.2% |
| Operating Income | $452.80M +281.9% |
-$248.93M +56.1% |
-$566.51M +12.1% |
-$644.74M +61.8% |
-$1.69B -304.7% |
-$416.72M -245.6% |
| Shares Outstanding | 162.58M +1.3% |
160.42M +15.0% |
139.51M +62.1% |
86.04M +13.4% |
75.84M +6.9% |
70.95M +119.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $70.44M | -16.6% | -70.6% |
| Net Income | September 30, 2025 | -$202.38M | -66.8% | -290.0% |
| Diluted EPS | September 30, 2025 | -$1.25 | -64.5% | -301.6% |
| Total Assets | September 30, 2025 | $1.18B | -31.1% | -11.7% |
| Cash and Equivalents | September 30, 2025 | $268.02M | -53.3% | +5.6% |
| Stockholders Equity | September 30, 2025 | -$156.67M | +70.2% | -516.4% |
| R&D Expense | September 30, 2025 | $98.27M | +12.7% | +24.0% |
| Operating Income | September 30, 2025 | -$178.02M | -32.8% | -276.1% |
| Shares Outstanding | September 30, 2025 | 162.47M | +1.4% | +0.2% |
- NOVAVAX INC reported Total Revenue of $1.12 billion for fiscal year 2025.
- NOVAVAX INC showed an increase of +64.7% in Total Revenue compared to the prior fiscal year.
- NOVAVAX INC reported Net Income of $440.30 million for fiscal year 2025.
- NOVAVAX INC showed an increase of +334.8% in Net Income compared to the prior fiscal year.
- NOVAVAX INC reported Diluted EPS of $2.58 per share for fiscal year 2025.
- NOVAVAX INC showed an increase of +309.8% in Diluted EPS compared to the prior fiscal year.
- NOVAVAX INC reported Total Assets of $1.18 billion for fiscal year 2025.
- NOVAVAX INC showed a decrease of -24.6% in Total Assets compared to the prior fiscal year.
- NOVAVAX INC reported Cash and Equivalents of $240.63 million for fiscal year 2025.
- NOVAVAX INC showed a decrease of -54.6% in Cash and Equivalents compared to the prior fiscal year.
- NOVAVAX INC reported Stockholders Equity of -$127.75 million for fiscal year 2025.
- NOVAVAX INC showed an increase of +79.5% in Stockholders Equity compared to the prior fiscal year.
- NOVAVAX INC reported R&D Expense of $342.32 million for fiscal year 2025.
- NOVAVAX INC showed a decrease of -12.5% in R&D Expense compared to the prior fiscal year.
- NOVAVAX INC reported Operating Income of $452.80 million for fiscal year 2025.
- NOVAVAX INC showed an increase of +281.9% in Operating Income compared to the prior fiscal year.
- NOVAVAX INC reported Shares Outstanding of 162.58 million shares for fiscal year 2025.
- NOVAVAX INC showed an increase of +1.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: